Hungarian drug Price Increases

5 February 1996

members of the Association of International Pharmaceutical Manufacturers in Hungary have decided not to raise their prices in 1996, following the planned state drug price rise of 35%-40% within the next month or so, which includes a 7.4% manufacturers' price rise, reports MTI Econews (Marketletter January 29).

The AIPM has said that delays in introducing the new drug price reimbursement system in Hungary means extra expenditure of 2 billion forint ($13.7 million) for the National Health Insurance Fund.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight